Companies /Healthcare

Transmedics Group Inc

NASDAQ: TMDX Medical Devices
$93.91
▲ $1.70 (+1.84%) today
Markets closed · 7:21pm ET

TMDX at a Glance

Valuation
Market cap
$3.2B
P/E ratio
24.9
Profitability
Revenue (TTM)
$727.7M
Profit margin
19.9%
EPS (TTM)
$3.70
Price
52-week range
$60 – $156
Street target
$104.55

Headquartered in Andover, MA Fiscal year ends December NASDAQ: TMDX transmedics.com

About TransMedics Group

TransMedics Group is a medical technology company focused on organ transplant therapy for patients with end-stage lung, heart and liver failure.

Its core platform is the Organ Care System (OCS), a portable extracorporeal warm perfusion and assessment system. OCS preserves donor organ quality, assesses organ viability before transplant and aims to increase donor organ utilization.

The company earns revenue in two ways:
- Net product revenue from OCS disposables and devices.
- Service revenue from its National OCS Program (NOP), a turnkey organ procurement and clinical service model.

Service revenue also includes an integrated transplant air logistics network. This network was expanded through a July 2026 strategic investment in PAD Aviation, which provides charter services. In October 2026, PAD Aviation won the company's first European transplant logistics tender, in Italy.

The development pipeline includes:
- Next-Generation OCS.
- The ENHANCE Heart trial; Part B received FDA IDE approval.
- The DENOVO Lung trial, which received FDA IDE approval.
- TransMedics Controlled Hypothermic Organ Preservation System (CHOPS), used as a control arm in both trials.
- OCS Kidney, targeting first-in-human use in the second half of 2027.

The company plans to launch OCS NOP in Italy, the Netherlands and Belgium. Its capital structure includes 1.50% convertible senior notes due 2028. Updated

Latest Activity

TMDXTransMedics Group
Q3 2026
EPS
$0.51
est $0.29+73.8%
Revenue
$203M
est $178M+14.0%

TransMedics raised full-year revenue guidance to $764 million to $774 million after its biggest quarter ever, before PAD Aviation contributes anything. Liver and heart volume through the National OCS Program is still compounding, and ENHANCE Heart Part B, DENOVO Lung and an OCS Kidney human study are all queued for 2027.

Quarterly EPS — reported vs estimate

TMDX Coverage

Frequently Asked Questions

What does TransMedics Group do?

TransMedics Group is a medical technology company focused on organ transplant therapy for patients with end-stage lung, heart and liver failure. Its core platform is the Organ Care System (OCS), a portable extracorporeal warm perfusion and assessment system.

What is the TMDX stock price target?

The Wall Street consensus 12-month price target for TMDX is $104.55.